v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Jul. 31, 2026
Jul. 31, 2025
Cash flows from operating activities    
Net loss $ (44,087) $ (25,826)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,664 2,028
Loss on disposal of property and equipment 292 280
Reserve for equipment and supplies 1,464 412
(Recovery) provision for uncollectible accounts receivable (817) 613
Amortization (accretion) of premiums (discounts) on securities, net (890)  
Loss on extinguishment of debt 6,304  
Amortization of debt discounts and issuance costs 408 469
Share-based compensation expense 9,517 4,579
Non-cash lease expense 103 61
Change in fair value of warrant liabilities 251 (2,909)
Changes in operating assets and liabilities:    
Disposable medical equipment supplies (908) (460)
Prepaid expenses and other current assets 246 140
Accounts receivable (48) (1,777)
Accounts payable (1,879) (2,896)
Accrued liabilities (4,727) (860)
Operating lease liabilities (190) (138)
Other long-term assets 2 10
Net cash used in operating activities (32,295) (26,274)
Cash flows from investing activities    
Purchases of property and equipment (8,335) (8,166)
Deposits for medical rental equipment 0 (103)
Refund of deposits for medical rental equipment 0 37
Purchase of marketable securities (13,017)  
Net cash used in investing activities (21,352) (8,232)
Cash flows from financing activities    
Proceeds from issuance of long-term debt 75,000  
Payment of debt issuance costs (3,193)  
Repayment of long-term debt (46,395)  
Payment of early termination fee on debt repayment (3,758)  
Payment of IPO offering costs   (1,875)
Payment of equity issuance costs (415)  
Deemed dividend for payments to third party on behalf of shareholder (172)  
Proceeds from stock option exercises 1,140  
Proceeds from employee stock purchase plan 1,298  
Tax withholdings on restricted stock unit vesting (1,010)  
Net cash provided by (used in) financing activities 22,495 (1,875)
Net decrease in cash, cash equivalents and restricted cash (31,152) (36,381)
Cash, cash equivalents and restricted cash    
Beginning of period 100,044 237,929
End of period 68,892 201,548
Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets    
Cash and cash equivalents 68,558 201,214
Restricted cash 334 334
Cash, cash equivalents and restricted cash 68,892 201,548
Non-cash investing and financing activities:    
Purchases of property and equipment in accrued liabilities and accounts payable 8,854 6,900
Debt Issuance Costs included in Accrued Liabilities and Accounts Payable 548  
Tax withholdings on restricted stock unit vesting in accrued liabilities 3,906  
Supplemental disclosure of cash flow information    
Income taxes paid (refunds received) 24 (39)
Interest paid $ 1,098 $ 1,423